Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.03 USD | +0.12% | -0.42% | -17.26% |
Apr. 23 | Argus Cuts Price Target on Gilead Sciences to $75 From $85 | MT |
Apr. 22 | Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.26% | 83.58B | |
+27.92% | 672B | |
+26.94% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.34% | 217B | |
+6.34% | 199B | |
-9.08% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead's Oncology Studies of Magrolimab-Azacitidine Drug Combination Placed on Partial Clinical Hold by FDA